real-time news and commentary for investors
Friday, Dec 14
2012, 4:35 PM
Dusa Pharmaceuticals (DUSA) reports preliminary results of Phase II clinical trials...
Dusa Pharmaceuticals (DUSA) reports preliminary results of Phase II clinical trials investigating the use of the Levulan Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment — after incubating for one, two or three hours — resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count.